

Reference: FOI.ICB-2526/216

Subject: Wegovy (semaglutide) and Mounjaro (tirzepatide) for Weight Loss or Weight Management

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
1. Please tell me how many patients within the ICB are currently taking Wegovy (semaglutide) for weight loss or weight management?	Based on access to GP data - 7 patients currently being prescribed Wegovy in general practice on NHS prescription.
2. If possible, please provide figures for the average current waiting time currently for patients to start taking Wegovy from referral from their GP.	The ICB do not hold this information.
3. Please tell me how many patients within the ICB are currently taking Mounjaro (tirzepatide) for weight loss or weight management?	105 patients currently being prescribed tirzepatide in general practice on NHS prescription who have SNOMED code indicating it is prescribed for obesity.
4. If possible, please provide figures for the average current waiting time for patients to start taking Wegovy* from referral from their GP.	The ICB do not hold this information. *To note: we have answered for Mounjaro (tirzepatide).
5. Please provide details of your current referral thresholds for patients to be prescribed Wegovy.	Access to the Specialist Weight Management service is covered by the below policy: Weight Management Service - Tier 3 and Tier 4 Service - BNSSG Healthier Together

6. Please provide details of your current referral thresholds for patients to be prescribed Mounjaro

Access to the Specialist Weight Management service is covered by the below policy: [Weight Management Service - Tier 3 and Tier 4 Service - BNSSG Healthier Together](#)

The information provided in this response is accurate as of 22 October 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.